Novavax, Inc., announced on 31 July 2013 that the public tender offer for
Isconova AB (publ) was declared wholly unconditional and that it will be
completed. Novavax, Inc., controlled after the initial acceptance period shares
representing approximately 97.4 per cent of the shares and votes in Isconova AB
(publ) and warrants representing 100 per cent of the outstanding warrants in
Isconova AB (publ).
Novavax, Inc. has also initiated a compulsory acquisition procedure regarding
the remaining shares in Isconova AB (publ).
Based on the above, the board of directors of Isconova AB (publ) considers that
it is no longer justified for Isconova AB (publ) to remain listed and has
therefore, on 21 August 2013, resolved to request that the shares of Isconova AB
(publ) are delisted from NASDAQ OMX First North Premier.
Last day for trading in the Isconova AB (publ) shares on NASDAQ OMX First North
Premier will preliminary be two weeks following NASDAQ OMX’s acceptance of
Isconova AB (publ)’s request for delisting, and will be announced as soon as
Isconova AB (publ) has received notice thereof from NASDAQ OMX.
The board of directors of Isconova AB (publ)
For more information, please contact:
Sven Andréasson, CEO of Isconova
Phone +46 701 60 60 60
Isconova AB (publ) discloses the information provided herein pursuant to the
Swedish Securities Market Act, the Swedish Financial Instruments Trading Act
and/or NASDAQ OMX First North Rulebook. This information was submitted for
publication on 21 August 2013 at 7:00pm (CET).
This press release has been published in Swedish and English. In the event of
any discrepancy in content between the language versions, the Swedish version
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
2321 Rosecrans Avenue.
El Segundo, CA 90245 Phone: (800) 307-6627 Fax: (800) 307-3567
25 Basinghall Street,
London EC2V 5HA
UK Phone: +1 866-465-8454